Business Context and Reporting Period
Company: GRI Bio, Inc. (GRI)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2025
Business Overview: GRI is a clinical-stage biopharmaceutical company developing therapies for inflammatory, fibrotic, and autoimmune disorders. Its lead candidate, GRI-0621, is an oral inhibitor of type 1 invariant Natural Killer T (iNKT) cells for idiopathic pulmonary fibrosis (IPF). A second candidate, GRI-0803, targets autoimmune disorders like lupus and multiple sclerosis.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(2,892) | $(5,938) | $(4,137) |
| Operating Expenses | $2,897 | $5,949 | $4,153 |
| Research & Development | $1,879 | $3,520 | $1,811 |
| General & Administrative | $1,018 | $2,429 | $2,342 |
| Cash and Cash Equivalents (End of Period) | $5,122 | $5,122 | $6,353 |
| Accumulated Deficit | $(45,678) | $(45,678) | $(35,670) |
| Net Cash Used in Operating Activities (YTD) | — | $(4,902) | $(4,344) |
| Net Cash Provided by Financing Activities (YTD) | — | $4,996 | $8,889 |
Note: The company has no product revenue. All figures are in thousands except per share data.
Material Changes vs. Prior Period
- Increased Burn Rate: Net loss for the six months ended June 30, 2025, increased to $5.9 million from $4.1 million in the prior year period. Operating expenses rose to $5.9 million from $4.2 million.
- R&D Acceleration: Research and development expenses surged by $1.7 million year-over-year (to $3.5 million), driven primarily by a $1.6 million increase in costs related to the GRI-0621 development program.
- Financing Activity: The company raised approximately $5.0 million in net proceeds during the first half of 2025, primarily through an April 2025 public offering ($4.0 million net) and an At-The-Market (ATM) facility ($0.8 million net in Q2).
- Share Count: Outstanding shares increased significantly from 525,485 at year-end 2024 to 2,496,800 as of June 30, 2025, due to equity issuances and the exercise of pre-funded warrants.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management states there is "substantial doubt" about the company's ability to continue as a going concern for one year from the filing date. Current cash ($5.1 million) is projected to fund operations only into the fourth quarter of 2025.
- Clinical Progress: Enrollment for the Phase 2a biomarker study of GRI-0621 for IPF was completed in July 2025. Topline results are expected in Q3 2025. Early data suggests an anti-fibrotic effect with no safety concerns observed in initial reviews.
- Capital Needs: The company intends to raise additional capital through equity or debt to fund future operations. Failure to secure funding could force reductions in spending or cessation of operations.
- Internal Control Weakness: Management identified a material weakness in internal controls related to the inaccurate computation of a non-cash deemed dividend associated with a warrant repricing transaction in late 2024. Remediation plans are underway.
- Subsequent Event: The "One Big Beautiful Bill Act" was enacted on July 4, 2025. Management does not currently expect it to materially impact the effective tax rate or cash flows.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for cash depletion and the status of any new financing discussions post-filing.
- Phase 2a Results: Monitor the release of topline data for the GRI-0621 IPF study expected in Q3 2025.
- Dilution Risk: Review the terms of outstanding warrants (Series E, C, D, etc.) and the remaining capacity under the ATM facility, as further equity raises will likely be necessary.
- Internal Controls: Assess the progress of remediation for the material weakness regarding warrant accounting.
- Regulatory Status: Confirm the status of the IND application for GRI-0803, which is currently paused pending funding.